New Products

PITTSBURGH — Mylan has launched a generic drug for treating a condition that causes heightened levels of the protein prolactin in the blood, the company said Thursday.

Mylan announced the launch of cabergoline tablets in the 0.5-mg strength, used for treating hyperprolactinemic disorders.

Various versions of the drug had sales of about $41.67 million during the 12-month period ending in September, according to IMS Health.

CANTON, Mass. — Bathroom wipes may be a popular alternative to toilet tissue, but they can also leave homeowners with clogged plumbing and put strain on city sewer systems. A new product aims to provide a solution.

Fresh Dab Toilet Paper Gel is a naturally formulated, water-soluble gel that is applied to toilet paper and then used like a wet wipe. Once the paper is flushed, Fresh Dab easily passes through pipes.

AUBURN HILLS, Mich. — Hair care brand Salon Grafix has officially announced the launch of its new Play It Big!, a collection of hair products.

Launching in early 2014, the new collection aims to set a new standard for daily glamour. Each product is enriched with a keratin protein complex to help strengthen hair while providing volume and body. Play It Big! hair sprays have a micro-mist diffuser cap that provides a salon-like misting application.

PETALUMA, Calif. — The Food and Drug Administration has approved a new topical drug for treating scars made by Oculus Innovative Sciences, the drug maker said Wednesday.

The FDA has approved Microcyn scar-management hydrogel, used to treat scars resulting from burns, surgery and trauma wounds. Oculus and a partnering company, Quinnova Pharmaceuticals, intend to start selling the drug in the first half of next year.

LONDON — Infirst Healthcare earlier this month secured the rights to market Dr. Cocoa, an award-winning cocoa-flavored pediatric cough remedy.

“Many cough treatments have deficiencies in their efficacy, safety and compliance profiles and Infirst Healthcare is committed to finding solutions that address these issues," Manfred Scheske, Infirst CEO said. "Introducing compliance optimized pediatric products that taste better to children is a step in this direction. We are excited about the start of our U.S. operations in the pediatric OTC market.

SILVER SPRING, Md. — The Food and Drug Administration has given tentative approval to a generic drug used to treat prostate disease, agency records showed.

The FDA granted tentative approval to Roxane Labs' dutasteride capsules in the 0.5-mg strength. The drug is a generic version of GSK's Avodart, used to treat benign prostatic hyperplasia.

Tentative approval means that a drug meets the agency's conditions for approval, but can't receive final approval until Avodart loses its patent protection, which will occur in 2015.

NEWARK, N.J. — Inergetics and the Podiatree Co. on Tuesday launched Intrinsix, a podiatry-exclusive nerve health support supplement enriched with calcium and vitamin D.

Developed alongside pharmacist, Robert Graci, Inergetics has created a unique formula to support healthy nerve function and specifically help diabetic patients who experience nerve-related symptoms in their extremities, which include tingling, pain, burning and loss of sensation, the company stated. 

SILVER SPRING, Md. — The Food and Drug Administration has given tentative approval to a generic drug for treating community-acquired pneumonia, agency records showed.

According to the FDA's website, the agency granted the preliminary authorization for Roxane Labs' linezolid oral suspension in the 100-mg-per-5-mL strength.